- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01884896
Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fasting Conditions
An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg of Ipca Laboratories Limited, India and 'Toprol-XL®' (Metoprolol Succinate) Extended Release Tablets 200 mg of Astrazeneca LP, USA In Healthy Adult Human Subjects Under Fasting Conditions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective of this pivotal study was to assess the bioequivalence between Test Product: Metoprolol Succinate 200 mg Ipca Laboratories Limited, India and the corresponding Reference Product: TOPROL-XL® (Metoprolol Succinate) extended release Tablets 200 mg of Astrazenica LP, USA under fasting condition in healthy adult human subjects in a randomized crossover study.
The study was conducted with 48 healthy adult subjects. In each study period, a single 200 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.
The duration of the clinical phase was approximately 11 days including washout period of at least 7 days between administrations of study drug in each study period.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380054
- Cliantha Research Limited
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 to 45 years old, both inclusive.
- Sex: Males and/or non-pregnant, non-lactating females.
- BMI: 18.5 to 24.9 weight in kg/(height in meter)2 both inclusive;
- Able to communicate effectively with study personnel and willingness to follow the protocol requirements as evidenced by written informed consent.
- Able to give written informed consent to participate in the study.
All volunteers must be judged by the principal or co-investigator or physician as normal and healthy during a pre-study safety assessment performed within 21 days of the first dose of study medication which will include:
- A physical examination with no clinically significant finding.
- Results within normal limits or clinically non-significant for the tests mentioned in List of Laboratory Parameters:
- Additional tests and/or examinations may be performed, if necessary, based on Principal Investigator discretion.
- All results will be assessed against the laboratory normal ranges current at the time of testing and a copy of the normal ranges used will be included in the study documentation.
Exclusion Criteria:
- History of allergic responses to Metoprolol Succinate or other related drugs, or any of its formulation ingredients.
- Have significant diseases or clinically significant abnormal findings during screening, [medical history, physical examination, laboratory evaluations, ECG, chest X-ray recording, obstetrics and gynecological history and examination along with PAP smear (for female volunteers) & transvaginal ultrasonography (for female volunteers)].
- Any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
- History or presence of bronchial asthma.
- Use of any hormone replacement therapy within 3 months prior to study medication dosing.
- A depot injection or implant of any drug within 3 months prior to administration of study medication.
- Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
- History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
- Smokers who smoke 10 or more cigarettes per day or 20 or more biddies per day or those who cannot refrain from smoking during the study period.
- History of difficulty with donating blood or difficulty in accessibility of veins.
- History of allergic response to heparin.
- A positive hepatitis screen (includes subtypes B & C).
- A positive test result for HIV antibody and / or syphilis (RPR/VDRL).
- Volunteers who have donated blood (1 unit or 450 mL) within 90 days prior to the initial dose of the study drug or have blood loss, excluding volume drawn at screening for this study, (≤100 mL within 30 days; ≤200 mL within 60 days; >200 mL within 90 days) prior to initial dose of study drug.
- History of difficulty in swallowing, or of any gastrointestinal disease which could affect drug absorption.
- Intolerance to venipuncture
- Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Co-Investigator, could contraindicate the volunteer's participation in this study.
- Volunteers who have received a known investigational drug within five elimination half life of the administered drug prior to the initial dose of study drug or who have participated in a clinical drug study or bioequivalence study within 90 days prior to the initial dose of study drug, whichever is greater.
- Found positive in urine test for drugs of abuse done before check-in of period I.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 'TOPROL-XL®' ER Tablets 200 mg
'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
|
1 * 200 mg tablet per day
Other Names:
1 * 200 mg tablet per day
Other Names:
|
Experimental: Metoprolol Succinate ER Tablet 200 mg
Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
|
1 * 200 mg tablet per day
Other Names:
1 * 200 mg tablet per day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bioequivalence is based on Cmax and AUC parameters.
Time Frame: 1 Month
|
Area Under Curve (AUC)and Cmax Sampling Hours: Pre-dose and at 1.0, 2.0, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0,11.0,
12.0, 13.0, 14.0, 16.0, 20.0, 24.0, 36.0 and 48.0 hours post dose.
|
1 Month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr. Manish Singhal, M.B.B.S, Cliantha Research Limited
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Metoprolol
Other Study ID Numbers
- BA1264350
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fasting
-
USDA, Western Human Nutrition Research CenterUniversity of California, DavisCompletedCardiovascular Risk Factor | Athletic Performance | Fasting | Resting Energy Expenditure | Intermittent FastingUnited States
-
Desitin Arzneimittel GmbHBioPharma Services, IncCompleted
-
Beth Israel Deaconess Medical CenterCompleted
-
Gaziosmanpasa Research and Education HospitalCompleted
-
Postgraduate Institute of Medical Education and...Completed
-
Chulalongkorn UniversityCompleted
-
IPCA Laboratories Ltd.Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
PT Novell Pharmaceutical LaboratoriesCompleted
Clinical Trials on Metoprolol Succinate ER Tablet 200 mg
-
IPCA Laboratories Ltd.Completed
-
SanionaCompleted
-
Impax Laboratories, LLCCompletedIdiopathic Parkinson's DiseaseUnited States
-
CytokineticsRecruitingObstructive Hypertrophic Cardiomyopathy (oHCM)United States, Netherlands, United Kingdom, France, Spain, China, Israel, Denmark, Italy, Germany, Hungary, Canada
-
TaiRx, Inc.CompletedAdvanced CancerTaiwan
-
IPCA Laboratories Ltd.Completed
-
ObsEva SATerminatedEndometriosisUnited States, Canada, Puerto Rico
-
Kissei Pharmaceutical Co., Ltd.CompletedEndometriosisUnited States, Austria, Bulgaria, Czechia, France, Poland, Romania, Spain, Ukraine, Hungary
-
Kissei Pharmaceutical Co., Ltd.Active, not recruitingEndometriosisUnited States, Austria, Bulgaria, Czechia, France, Poland, Romania, Spain, Ukraine